User login
The American Association for Cancer Research has announced the launch of Cancer Immunology Research, a peer-reviewed journal for original articles on advances in cancer immunology.
The new journal is receiving manuscripts for consideration for publication through its website, according to a press release. The journal is scheduled to launch online at the 2013 AACR annual meeting, and in print with monthly issues starting in June 2013.
The journal will highlight research from all areas of cancer immunology. Potential topics include: tumor-promoting inflammation, cancer antigens, vaccines, antibodies, cellular therapy, cytokines, endogenous antitumor immunity, immune regulation, immune suppression, immunomodulatory effects of cancer treatment, emerging technologies, and clinical investigations.
Plans for regular features include Masters of Immunology – primers on immunology topics from leaders in the field – and Cancer Immunology at the Crossroads – perspectives on the relationship between immunology and other areas of cancer research and allied disciplines.
Dr. Glenn Dranoff, professor of medicine at Dana-Farber Cancer Institute and Harvard Medical School, Boston, is slated to serve as the founding editor-in-chief of Cancer Immunology Research. Dr. Dranoff also leads the Dana-Farber/Harvard Cancer Center Program in Cancer Immunology.
The American Association for Cancer Research has announced the launch of Cancer Immunology Research, a peer-reviewed journal for original articles on advances in cancer immunology.
The new journal is receiving manuscripts for consideration for publication through its website, according to a press release. The journal is scheduled to launch online at the 2013 AACR annual meeting, and in print with monthly issues starting in June 2013.
The journal will highlight research from all areas of cancer immunology. Potential topics include: tumor-promoting inflammation, cancer antigens, vaccines, antibodies, cellular therapy, cytokines, endogenous antitumor immunity, immune regulation, immune suppression, immunomodulatory effects of cancer treatment, emerging technologies, and clinical investigations.
Plans for regular features include Masters of Immunology – primers on immunology topics from leaders in the field – and Cancer Immunology at the Crossroads – perspectives on the relationship between immunology and other areas of cancer research and allied disciplines.
Dr. Glenn Dranoff, professor of medicine at Dana-Farber Cancer Institute and Harvard Medical School, Boston, is slated to serve as the founding editor-in-chief of Cancer Immunology Research. Dr. Dranoff also leads the Dana-Farber/Harvard Cancer Center Program in Cancer Immunology.
The American Association for Cancer Research has announced the launch of Cancer Immunology Research, a peer-reviewed journal for original articles on advances in cancer immunology.
The new journal is receiving manuscripts for consideration for publication through its website, according to a press release. The journal is scheduled to launch online at the 2013 AACR annual meeting, and in print with monthly issues starting in June 2013.
The journal will highlight research from all areas of cancer immunology. Potential topics include: tumor-promoting inflammation, cancer antigens, vaccines, antibodies, cellular therapy, cytokines, endogenous antitumor immunity, immune regulation, immune suppression, immunomodulatory effects of cancer treatment, emerging technologies, and clinical investigations.
Plans for regular features include Masters of Immunology – primers on immunology topics from leaders in the field – and Cancer Immunology at the Crossroads – perspectives on the relationship between immunology and other areas of cancer research and allied disciplines.
Dr. Glenn Dranoff, professor of medicine at Dana-Farber Cancer Institute and Harvard Medical School, Boston, is slated to serve as the founding editor-in-chief of Cancer Immunology Research. Dr. Dranoff also leads the Dana-Farber/Harvard Cancer Center Program in Cancer Immunology.
